Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
05 Marzo 2024 - 10:30PM
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a
clinical-stage oncology company developing innovative, full-length
multispecific antibodies (Biclonics® and Triclonics®), today
announced the publication of an abstract highlighting the
preclinical evaluation of the bispecific antibody zenocutuzumab
(Zeno) for poster presentation at the American Association for
Cancer Research (AACR) Annual Meeting 2024 taking place in San
Diego, CA April 5-10, 2024.
The abstract describes Zeno’s activity in preclinical models
representing different tumor types expressing high neuregulin 1
(NRG1) levels. High NRG1 expression is associated with poorer
prognosis in certain cancers and resistance to standard therapies.
The anti-tumor efficacy of Zeno in vivo against a panel of 28
patient-derived xenograft (PDX) models representing different tumor
types was examined. The results show that Zeno significantly
inhibited tumor growth in seven high-NRG1-expressing PDX models
representing multiple different tumor types.
Presentation Details:
Title: Zenocutuzumab, a HER2xHER3 bispecific
antibody, is effective in cancer models with high NRG1
expression.Session Category: Experimental and
Molecular TherapeuticsSession: Antibody-Drug
Conjugates and Bispecific AntibodiesDate: Monday,
April 8, 2024Time: 9:00 am-12:30 p.m.
PTLocation: Poster Section 23Poster
#: 14Abstract #: 1903
The full abstract is available on the AACR website. The poster
will be available on the Merus website at the start of the
session.
Zeno is being investigated in the phase 1/2 eNRGy trial and
Early Access Program which are assessing the safety and anti-tumor
activity of Zeno monotherapy in NRG1+ cancer. Based on recent
productive and collaborative discussions with the U.S. Food &
Drug Administration, we believe we will have sufficient clinical
data in the first half of 2024 to support potential Biologics
License Application submissions in NRG1+ non-small cell lung cancer
and NRG1+ pancreatic cancer.
About ZenoZeno is an antibody-dependent
cell-mediated cytotoxicity (ADCC)-enhanced Biclonics® that
utilizes the Merus Dock & Block® mechanism to inhibit
the neuregulin/HER3 tumor-signaling pathway in solid tumors with
NRG1 gene fusions (NRG1+ cancer). Through its unique mechanism of
binding to HER2 and potently blocking the interaction of HER3 with
its ligand NRG1 or NRG1-fusion proteins, Zeno has the potential to
be particularly effective against NRG1+ cancer. In preclinical
studies, Zeno also potently inhibits HER2/HER3 heterodimer
formation and tumor growth in models harboring NRG1 fusions.
About Merus N.V.Merus is a clinical-stage
oncology company developing innovative full-length human bispecific
and trispecific antibody therapeutics, referred to as
Multiclonics®. Multiclonics® are manufactured using industry
standard processes and have been observed in preclinical and
clinical studies to have several of the same features of
conventional human monoclonal antibodies, such as long half-life
and low immunogenicity. For additional information, please visit
Merus’ website, X and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding the clinical
development of Zeno, preclinical activity, the translation, if any,
of such activity in clinical development; and our belief that we
will have sufficient clinical data in the first half of 2024 to
support potential Biologics License Application submissions in
NRG1+ non-small cell lung cancer and NRG1+ pancreatic cancer. These
forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, the
following: our need for additional funding, which may not be
available and which may require us to restrict our operations or
require us to relinquish rights to our technologies or Biclonics®,
Triclonics® and multispecific antibody candidates; potential delays
in regulatory approval, which would impact our ability to
commercialize our product candidates and affect our ability to
generate revenue; the lengthy and expensive process of clinical
drug development, which has an uncertain outcome; the unpredictable
nature of our early stage development efforts for marketable drugs;
potential delays in enrollment of patients, which could affect the
receipt of necessary regulatory approvals; our reliance on third
parties to conduct our clinical trials and the potential for those
third parties to not perform satisfactorily; impacts of the market
volatility; we may not identify suitable Biclonics® or bispecific
antibody candidates under our collaborations or our collaborators
may fail to perform adequately under our collaborations; our
reliance on third parties to manufacture our product candidates,
which may delay, prevent or impair our development and
commercialization efforts; protection of our proprietary
technology; our patents may be found invalid, unenforceable,
circumvented by competitors and our patent applications may be
found not to comply with the rules and regulations of
patentability; we may fail to prevail in potential lawsuits for
infringement of third-party intellectual property; and our
registered or unregistered trademarks or trade names may be
challenged, infringed, circumvented or declared generic or
determined to be infringing on other marks.
These and other important factors discussed under the caption
“Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2023 filed with the Securities and Exchange
Commission, or SEC, on February 28, 2024, and our other reports
filed with the SEC, could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change, except as required
under applicable law. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent
to the date of this press release.
Biclonics®, Triclonics® and Multiclonics® are registered
trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
Corp Comms/IR
617-230-4165
k.farren@merus.nl
Grafico Azioni Merus NV (NASDAQ:MRUS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Merus NV (NASDAQ:MRUS)
Storico
Da Set 2023 a Set 2024